222036-66-0

Basic information

• Product Name: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI)
• Synonyms: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI);5-amino-2,3-dihydro-1H-Isoindol-1-one;5-aminoisoindolin-1-one;1H-Isoindol-1-one, 5-amino-2,3-dihydro;5-aMino-2,3-dihydro- Isoindol-1-one;5-aMinoisoindoline-1-one
• CAS NO: 222036-66-0
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.17
• EINECS: 1592732-453-0
• Product Categories: AMINEPRIMARY;Quinolines
• Mol File: 222036-66-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 197-199 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 520.034 °C at 760 mmHg
• Flash Point: 268.307 °C
• Appearance: /
• Density: 1.307g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.654
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 15.12±0.20(Predicted)
• CAS DataBase Reference: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI)(222036-66-0)
• EPA Substance Registry System: 1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI)(222036-66-0)

Safety Data

• Hazardous Substances Data: 222036-66-0(Hazardous Substances Data)

Usage

Description

1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI), also known as 5-Aminoisoindolin-1-one, is an organic compound with a unique isoindolone skeleton. It is characterized by the presence of an amino group attached to the 5-position of the isoindolone ring, which confers specific chemical and biological properties to the molecule.

Uses

Used in Pharmaceutical Industry:
1H-Isoindol-1-one,5-amino-2,3-dihydro-(9CI) is used as a key intermediate in the synthesis of novel and potent glycoprotein IIb-IIIa (GP IIb-IIIa) receptor antagonists. These antagonists are crucial in the development of therapeutic agents for various medical conditions, particularly those involving blood clotting and cardiovascular diseases. The unique structure of 5-Aminoisoindolin-1-one allows for the design of highly specific and effective GP IIb-IIIa receptor antagonists, which can potentially improve patient outcomes and reduce the risk of complications associated with existing treatments.

InChI:InChI=1/C8H8N2O/c9-6-1-2-7-5(3-6)4-10-8(7)11/h1-3H,4,9H2,(H,10,11)

Upstream product

• 2518-24-3 3-aminophthalimide 
• 110568-64-4 2,3-Dihydro-6-nitro-1H-isoindol-1-on 
• 133446-99-8 2-bromomethyl-4-nitro-benzoic acid methyl ester 
• 1357104-53-0 C₁₀H₇F₃N₂O₂ 
• 1357104-48-3 C₁₈H₁₅F₃N₂O₃ 
• 552330-86-6 5-bromoisoindolin-1-one 
• 62621-09-4 methyl 2-methyl-4-nitrobenzoate 
• 1975-51-5 2-methyl-4-nitrobenzoic acid 
• 1113057-04-7 ethyl 4-amino-2-aminomethyl-benzoate monohydrochloride 

Downstream Products

• 1571073-74-9 1-(4-((2-((1-oxoisoindolin-5-yl)amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)-3-(1-(p-tolyl)-3-(trimethylsilyl)-1H-pyrazol-5-yl)urea 
• 1401461-58-2 1-(7-(3,4-dimethoxyphenylamino)thiazolo[5,4-d]pyrimidin-5-yl)-N-(1-oxoisoindolin-5-yl)piperidine-3-carboxamide 

Relevant articles and documents

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates

We report herein the design, synthesis, and structure-activity relationship studies of conformationally restricted mutilin 14-carbamates based on the structure of SB-222734. The antibacterial activities of these newly synthesized compounds were also evaluated and compared with linezolid and retapamulin. Results showed that most of the target compounds exhibit good potency in inhibiting the growth of Gram-positive bacteria including Methicillin- susceptible Staphylococcus aureus MSSA (MIC: 0.0625-2 μg/mL), Methicillin-resistant S. aureus MRSA (MIC: 0.0625-2 μg/mL), Methicillin-susceptible Staphylococcus epidermidis MSSE (MIC: 0.0625-2 μg/mL), Methicillin-resistant S. epidermidis MRSE (MIC: 0.0625-2 μg/mL), and Streptococcus pneumonia (MIC: 0.0625-4 μg/mL). In particular, three remarkable compounds of this series (12l, 12m, and 21l) exhibited comparable in vitro antibacterial profiles to that of retapamulin.